These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 20726794)

  • 21. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
    Stebbins JL; Zhang Z; Chen J; Wu B; Emdadi A; Williams ME; Cashman J; Pellecchia M
    J Med Chem; 2007 Dec; 50(26):6607-17. PubMed ID: 18038971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression.
    Barash S; Wang W; Shi Y
    Biochem Biophys Res Commun; 2002 Jun; 294(4):835-42. PubMed ID: 12061783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.
    Liu Y; Jiang J; Richardson PL; Reddy RD; Johnson DD; Kati WM
    Anal Biochem; 2006 Sep; 356(1):100-7. PubMed ID: 16737676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MISS-Prot: web server for self/non-self discrimination of protein residue networks in parasites; theory and experiments in Fasciola peptides and Anisakis allergens.
    González-Díaz H; Muíño L; Anadón AM; Romaris F; Prado-Prado FJ; Munteanu CR; Dorado J; Sierra AP; Mezo M; González-Warleta M; Gárate T; Ubeira FM
    Mol Biosyst; 2011 Jun; 7(6):1938-55. PubMed ID: 21468430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein-ligand docking using hamiltonian replica exchange simulations with soft core potentials.
    Luitz MP; Zacharias M
    J Chem Inf Model; 2014 Jun; 54(6):1669-75. PubMed ID: 24855894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
    Ni S; Yuan Y; Huang J; Mao X; Lv M; Zhu J; Shen X; Pei J; Lai L; Jiang H; Li J
    J Med Chem; 2009 Sep; 52(17):5295-8. PubMed ID: 19691347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple stochastic fingerprints towards mathematical modeling in biology and medicine 2. Unifying Markov model for drugs side effects.
    Cruz-Monteagudo M; González-Díaz H; Uriarte E
    Bull Math Biol; 2006 Oct; 68(7):1527-54. PubMed ID: 16847720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined prediction of transmembrane topology and signal peptide of beta-barrel proteins: using a hidden Markov model and genetic algorithms.
    Zou L; Wang Z; Wang Y; Hu F
    Comput Biol Med; 2010 Jul; 40(7):621-8. PubMed ID: 20488436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships (SAR) research of thiourea derivatives as dual inhibitors targeting both HIV-1 capsid and human cyclophilin A.
    Chen K; Tan Z; He M; Li J; Tang S; Hewlett I; Yu F; Jin Y; Yang M
    Chem Biol Drug Des; 2010 Jul; 76(1):25-33. PubMed ID: 20456372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mass spectrometry-based thermal shift assay for protein-ligand binding analysis.
    West GM; Thompson JW; Soderblom EJ; Dubois LG; Dearmond PD; Moseley MA; Fitzgerald MC
    Anal Chem; 2010 Jul; 82(13):5573-81. PubMed ID: 20527820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformational energies and entropies of peptides, and the peptide-protein binding problem.
    Unal EB; Gursoy A; Erman B
    Phys Biol; 2009 Jun; 6(3):036014. PubMed ID: 19549999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cis/trans isomerization in HIV-1 capsid protein catalyzed by cyclophilin A: insights from computational and theoretical studies.
    Agarwal PK
    Proteins; 2004 Aug; 56(3):449-63. PubMed ID: 15229879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An FKBP12 binding assay based upon biotinylated FKBP12.
    Carreras CW; Fu H; Santi DV
    Anal Biochem; 2001 Nov; 298(1):57-61. PubMed ID: 11673895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides.
    Wiedemann U; Boisguerin P; Leben R; Leitner D; Krause G; Moelling K; Volkmer-Engert R; Oschkinat H
    J Mol Biol; 2004 Oct; 343(3):703-18. PubMed ID: 15465056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligopeptide cyclophilin inhibitors: a reassessment.
    Schumann M; Jahreis G; Kahlert V; Lücke C; Fischer G
    Eur J Med Chem; 2011 Nov; 46(11):5556-61. PubMed ID: 21963115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdominant genetics, peptide inhibitors and drug targets.
    Kamb A; Teng DH
    Curr Opin Mol Ther; 2000 Dec; 2(6):662-9. PubMed ID: 11249744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NovoHMM: a hidden Markov model for de novo peptide sequencing.
    Fischer B; Roth V; Roos F; Grossmann J; Baginsky S; Widmayer P; Gruissem W; Buhmann JM
    Anal Chem; 2005 Nov; 77(22):7265-73. PubMed ID: 16285674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A docking study using atomistic conformers generated via elastic network model for cyclosporin A/cyclophilin A complex.
    Akten ED; Cansu S; Doruker P
    J Biomol Struct Dyn; 2009 Aug; 27(1):13-26. PubMed ID: 19492859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting prolyl isomerase activity by hybrid organic-inorganic molecules containing rhodium(II) fragments.
    Coughlin JM; Kundu R; Cooper JC; Ball ZT
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5203-6. PubMed ID: 25442313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential responses of the backbone and side-chain conformational dynamics in FKBP12 upon binding the transition-state analog FK506: implications for transition-state stabilization and target protein recognition.
    Brath U; Akke M
    J Mol Biol; 2009 Mar; 387(1):233-44. PubMed ID: 19361439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.